Impact of ACSL4 on the prognosis of hepatocellular carcinoma: Association with cancer‐associated fibroblasts and the tumour immune microenvironment

Abstract Background & Aims Recently, the association between hepatocellular carcinoma (HCC) and ferroptosis has been the focus of much attention. The expression of long chain fatty acyl‐CoA ligase 4 (ACSL4), a marker of ferroptosis, in tumour tissue is related to better prognosis in various cancers. In HCC, ACSL4 expression indicates poor prognosis and is related to high malignancy. However, the mechanism remains to be fully understood. Methods We retrospectively enrolled 358 patients with HCC who had undergone hepatic resection. Immunohistochemistry (IHC) for ACSL4 was performed. Factors associated with ASCL4 expression were investigated by spatial transcriptome analysis, and the relationships were investigated by IHC. The association between ACSL4 and the tumour immune microenvironment was examined in a public dataset and investigated by IHC. Results Patients were divided into ACSL4‐positive ( n = 72, 20.1%) and ACSL4‐negative ( n = 286, 79.9%) groups. ACSL4 positivity was significantly correlated with higher α‐fetoprotein ( p = .0180) and more histological liver fibrosis ( p = .0014). In multivariate analysis, ACSL4 positivity was an independent prognostic factor ( p < .0001). Spatial transcriptome analysis showed a positive correlation between ACSL4 and cancer‐associated fibroblasts; this relationship was confirmed by IHC. Evaluation of a public dataset showed the correlation between ACSL4 and exhausted tumour immune microenvironment; this relationship was also confirmed by IHC. Conclusion ACSL4 is a prognostic factor in HCC patients and its expression was associated with cancer‐associated fibroblasts and anti‐tumour immunity.